Rivaroxaban safety in babies under 2 with blood clots
Treatments studied
Part of Heart & circulation clinical trials.
This study looks at how rivaroxaban (and sometimes other blood thinners) are used in babies under 2 who have venous thromboembolism (VTE), a blood clot in a vein. It gathers real-world safety information to help doctors understand how well this treatment works and what side effects may happen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is under 2 years old at the time the study starts
- Your child has started a blood thinner treatment within the last 6 months (or since birth if under 6 months)
- The blood clot (VTE) diagnosis happened recently (within the last 30 days in the hospital record)
- For children 6 months to 2 years: there is at least 6 months of medical history available before treatment starts
- For children under 6 months: there is medical history available since birth
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood thinner called rivaroxaban (a pill) works well for older Chinese patients who have had a blood clot in their lungs and are now on long-term treatment. It aims to see if it's safe and effective for this group.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
This trial compares close monitoring (“watch and wait”) versus taking the blood thinner rivaroxaban in people with a small type of lung blood clot. It aims to find out whether low-risk patients can safely avoid or reduce anticoagulation while still staying healthy.
This study tests a blood thinner called rivaroxaban in children who have a blood clot inside the heart. The goal is to see if it safely and effectively dissolves the clot, potentially avoiding the need for stronger treatments.
This study looks at how a blood thinner called rivaroxaban enters breast milk after delivery. It may help women who need this medication while breastfeeding.
This trial studies whether rivaroxaban (a blood thinner) can help prevent dangerous clots in children age 2 and older who have “giant” coronary artery aneurysms after Kawasaki disease. Doctors will see if it’s safe and tolerable for children who are also on standard anti-clot/anti-platelet medications for the next 3 months.
Hear when a new Venous Thromboembolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.